Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01928537
Title Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Onconova Therapeutics, Inc.

bone marrow cancer


Rigosertib Sodium

Age Groups: adult
Covered Countries USA

No variant requirements are available.